These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 6147109)

  • 21. Neurohormonal activation and the response to converting enzyme inhibitors in congestive heart failure.
    Kubo SH
    Circulation; 1990 Feb; 81(2 Suppl):III107-14. PubMed ID: 2137052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neurohumoral mechanisms in cardiocirculatory decompensation].
    Grassi G; Mancia G
    Ann Ital Med Int; 1994 Oct; 9 Suppl():61S-67S. PubMed ID: 7857760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responses of vasoactive hormones in congestive cardiac failure.
    Johnston CI; Arnolda LF; Tsunoda K; Phillips PA; Hodsman GP
    Can J Physiol Pharmacol; 1987 Aug; 65(8):1706-11. PubMed ID: 2961425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.
    Rehsia NS; Dhalla NS
    Heart Fail Rev; 2010 Jan; 15(1):85-101. PubMed ID: 19763821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of heart failure: the role of neurohumoral activation.
    Middlekauff HR; Mark AL
    Intern Med; 1998 Feb; 37(2):112-22. PubMed ID: 9550589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients.
    Lambert GW; Kaye DM; Lefkovits J; Jennings GL; Turner AG; Cox HS; Esler MD
    Circulation; 1995 Oct; 92(7):1813-8. PubMed ID: 7545554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function.
    Elsner D
    Eur Heart J; 1995 Dec; 16 Suppl N():52-8. PubMed ID: 8682062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hypertrophy due to left cardiac insufficiency: role of the neurohumoral system].
    Lerch R; Montessuit C
    Praxis (Bern 1994); 1997 Feb; 86(7):238-41. PubMed ID: 9139340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baroreceptor-mediated release of vasopressin in patients with chronic congestive heart failure and defective sympathetic responsiveness.
    Manthey J; Dietz R; Opherk D; Osterziel KJ; Leinberger H; Kübler W
    Am J Cardiol; 1992 Jul; 70(2):224-8. PubMed ID: 1626511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure.
    Francis GS
    Am Heart J; 1989 Sep; 118(3):642-8. PubMed ID: 2570521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurohumoral and hemodynamic changes in congestive heart failure: lack of correlation and evidence of compensatory mechanisms.
    Rouleau JL; Kortas C; Bichet D; de Champlain J
    Am Heart J; 1988 Sep; 116(3):746-57. PubMed ID: 2970771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased plasma arginine vasopressin levels in patients with congestive heart failure.
    Goldsmith SR; Francis GS; Cowley AW; Levine TB; Cohn JN
    J Am Coll Cardiol; 1983 Jun; 1(6):1385-90. PubMed ID: 6343460
    [No Abstract]   [Full Text] [Related]  

  • 33. The acute response of plasma norepinephrine, renin activity, and arginine vasopressin to short-term nitroprusside and nitroprusside withdrawal in patients with congestive heart failure.
    Francis GS; Olivari MT; Goldsmith SR; Levine TB; Pierpont G; Cohn JN
    Am Heart J; 1983 Dec; 106(6):1315-20. PubMed ID: 6359844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms and implications of autonomic nervous system dysfunction in heart failure.
    Middlekauff HR
    Curr Opin Cardiol; 1997 May; 12(3):265-75. PubMed ID: 9243084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneous neurohormonal fluctuation in chronic congestive heart failure.
    Kirlin PC; Dansby C; Laird C; Willis PW
    Am J Cardiol; 1988 Jul; 62(1):150-1. PubMed ID: 2898206
    [No Abstract]   [Full Text] [Related]  

  • 36. Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? II. Protagonist's viewpoint.
    Swedberg K
    J Am Coll Cardiol; 1988 Aug; 12(2):550-4. PubMed ID: 2899099
    [No Abstract]   [Full Text] [Related]  

  • 37. Recognized molecular mechanisms of heart failure: approaches to treatment.
    Ceconi C; Cargnoni A; Curello S; Ferrari R
    Rev Port Cardiol; 1998 Oct; 17 Suppl 2():II79-91. PubMed ID: 9835784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasopressin, renin and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy.
    Riegger GA; Kochsiek K
    Am J Cardiol; 1986 Aug; 58(3):300-3. PubMed ID: 3526857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurohumoral mechanisms in heart failure: role in pathogenesis, therapy, and drug tolerance.
    Dzau VJ; Hollenberg NK; Williams GH
    Fed Proc; 1983 Dec; 42(15):3162-9. PubMed ID: 6357858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure.
    Pedersen EB; Danielsen H; Jensen T; Madsen M; Sørensen SS; Thomsen OO
    Eur J Clin Invest; 1986 Feb; 16(1):56-60. PubMed ID: 3084274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.